GlassScriptPhysician profile
Samantha Burton
NPI 1013794825
$1,890.87
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $482 · 2024: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $351.62 | 2023-2024 | Rexulti |
| Tris Pharma INC | $301.19 | 2023-2024 | Dyanavel Xr |
| Abbvie INC. | $250.66 | 2023-2024 | |
| Lundbeck LLC | $169.78 | 2023-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $152.62 | 2023-2024 | Jornay Pm |
| Corium, LLC | $138.65 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $92.04 | 2023-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.88 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $77.30 | 2024 | Spravato |
| Noven Therapeutics, LLC | $58.70 | 2024 | Xelstrym |
| Alkermes, INC. | $54.58 | 2023 | Aristada, Lybalvi |
| Tempus Ai, INC | $51.51 | 2024 | Tempus Pixel |
| Takeda Pharmaceuticals U.S.A., INC. | $39.33 | 2023-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $23.96 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $23.50 | 2024 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $14.55 | 2024 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Burton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.